CSIMarket
 
Idexx Laboratories Inc  (IDXX)
Other Ticker:  
 
 
Price: $433.2800 $0.28 0.065%
Day's High: $434.48 Week Perf: 4.53 %
Day's Low: $ 428.75 30 Day Perf: -8.45 %
Volume (M): 656 52 Wk High: $ 583.39
Volume (M$): $ 284,102 52 Wk Avg: $504.30
Open: $430.01 52 Wk Low: $404.74



 Market Capitalization (Millions $) 35,987
 Shares Outstanding (Millions) 83
 Employees 11,000
 Revenues (TTM) (Millions $) 3,843
 Net Income (TTM) (Millions $) 866
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 124

Idexx Laboratories Inc
IDEXX Laboratories Inc. Overview

IDEXX Laboratories Inc. is a prominent global company specializing in diagnostics, software solutions, and services for the veterinary, livestock, and poultry industries. Established in 1983 and headquartered in Westbrook, Maine, United States, IDEXX has developed a reputation as a leader in animal health, providing veterinarians, livestock producers, and poultry farmers with cutting-edge technology and support to improve animal care and management.

Product Offerings

The company offers a wide variety of products and services designed to enhance animal health management. Some key product categories include:

1. Diagnostic Tests: IDEXX manufactures an array of diagnostic tests tailored for the detection of infectious diseases in animals. Notable examples include tests for parvovirus, Lyme disease, and feline leukemia. These tests are crucial for early detection and treatment of various illnesses in pets and livestock.

2. Point-of-Care Analyzers: IDEXXs point-of-care testing systems, such as the IDEXX VetLab Station and the IDEXX SNAP Pro Analyzer, are designed to deliver quick and accurate test results. This immediacy enables veterinarians to make rapid, informed decisions that lead to improved patient outcomes.

3. Imaging Systems: The company also provides imaging solutions for veterinary practices, enhancing diagnostic capabilities through advanced imaging technology. This allows for better visualization of animal health issues and more effective treatment planning.

4. Software Solutions: IDEXX offers several software products that streamline veterinary practice management. IDEXX Neo, for instance, is a cloud-based practice management software that simplifies various operational tasks such as workflow optimization, billing, appointment scheduling, and direct communication with clients. This software enhances client engagement and overall patient care.

5. Livestock and Poultry Solutions: In addition to veterinary services, IDEXX provides diagnostic solutions and monitoring systems for livestock and poultry health, helping farmers manage herd health, detect diseases early, and comply with regulations.

Global Presence and Workforce

IDEXX Laboratories operates in over 175 countries, making it a truly global entity in the animal health industry. The company has a workforce of more than 9,000 employees who are dedicated to innovation, research, and providing high-quality service to clients.

Financial Performance

IDEXX has achieved impressive financial growth, generating over $2 billion in annual revenue. This growth reflects the increasing demand for veterinary diagnostics and animal health products, driven by a greater focus on pet wellness, livestock productivity, and food safety.

Commitment to Innovation

A significant aspect of IDEXX's success is its commitment to research and development. The company invests heavily in innovative technologies and solutions aimed at improving animal health care. This continued focus on innovation has resulted in the launch of numerous groundbreaking products, keeping IDEXX at the forefront of the animal healthcare industry.

Workplace Recognition

IDEXX Laboratories has been recognized multiple times as one of the best places to work in the United States. This recognition is attributed to the companys strong corporate culture, commitment to employee development, and focus on creating a positive work environment.

Conclusion

IDEXX Laboratories Inc. stands as a leader in the animal healthcare space through its comprehensive range of diagnostic products, innovative software solutions, and commitment to research and development. With a widespread global presence and a dedicated workforce, IDEXX continues to make significant contributions to veterinary medicine and livestock health, enhancing the quality of care available to animals worldwide.


   Company Address: One IDEXX Drive Westbrook 4092 ME
   Company Phone Number: 556-0300   Stock Exchange / Ticker: NASDAQ IDXX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AGIO        31.74% 
ELAN        12.02% 
ZTS        0.94% 
• View Complete Report
   



Idexx Laboratories Inc

Idexx Laboratories Inc. Shows Strong Performance in First Quarter of 2024

The stock market has been closely monitoring the latest financial results of Idexx Laboratories Inc. for the first quarter of 2024. The company's revenue saw a significant increase of 7.096% to $964.07 million compared to the previous year's first quarter, where revenue was at $900.20 million. This growth in revenue is a positive sign for investors, indicating that the company is performing well and generating more income.
Income per share also saw a notable increase of 10.2% to $2.81 per share, compared to $2.55 in the prior year's first quarter. This shows that the company's profitability is improving, which is always a key aspect that investors look for when considering investing in a stock.

Idexx Laboratories Inc

In Vitro & In Vivo Diagnostic Substances Company Reports Strong Revenue Growth in Q4 20232.

The financial results of Idexx Laboratories Inc for the fourth quarter of 2023 paint a mixed picture of their performance. On one hand, the company saw a significant increase in revenue of 8.762% to $901.16 million compared to the previous year. This growth is a positive sign of the company's ability to generate more income and attract more customers.
Similarly, the increase in EPS by 11.69% to $2.32 per share is also a good indicator of the company's profitability and efficiency in managing costs. These numbers show that Idexx Laboratories Inc is on a solid financial footing and is able to deliver value to its shareholders.

Idexx Laboratories Inc

Idexx Laboratories Inc: Achieving Remarkable Financial Success in Q3 2023

IDEXX Laboratories Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, reported its financial results for the third quarter of 2023, which ended on September 30. The company's revenue increased by 8.711% to $914.98 million compared to $841.66 million in the same period last year. This growth was driven by strong performance in the Companion Animal Group (CAG) and Water segments, with CAG revenue growing by 9% and Water revenue growing by 9%.
IDEXX also posted a significant increase in income, with a rise of 17.67% to $2.53 per share, compared to $2.15 per share in the prior year reporting period. The company's net income for the July to September 30 fiscal timeframe increased by 17.29% to $212.231 million, compared to net earnings of $180.938 million in the same period last year.

Idexx Laboratories Inc

Remarkable 9.655% Revenue Surge Propels Idexx Laboratories Inc to a Stellar Fiscal Performance; EPS Skyrockets by 71.15%



Idexx Laboratories Inc, a global leader in veterinary diagnostics and software solutions, has recently released its financial results for the second quarter of 2023. These results highlight the company's impressive growth in earnings per share (EPS) and revenue, as well as improvements in profit margins. In addition, the article will provide context by discussing Idexx Laboratories Inc's recent share performance.
Financial Results:
1. EPS Elevation: Idexx Laboratories Inc witnessed a significant increase in EPS of 71.15%, reaching $2.67 in the second quarter of 2023. This marks substantial growth compared to $2.55 per share in the prior reporting season.

Idexx Laboratories Inc

Very balanced improvement for the company amid the financial three months closing Mar 31 2023

Despite the positive financial results reported by Idexx Laboratories Inc in the first quarter of 2023, there are several reasons why investors should be cautious about investing in this company. Firstly, while the return on assets (ROA) has improved compared to the previous quarter, there are still three healthcare companies with a higher ROA. This suggests that Idexx may not be performing as well as some of its competitors in the industry.
Furthermore, while revenue and income per share have increased, it is important to note that this growth is lower than in the previous quarter. Revenue increased by 7.608% in the January to March 31 2023 span, compared to growth of 8.645% in the previous quarter. Similarly, income per share grew by 12.33% in the first quarter of 2023, compared to growth of 22.78% in the previous quarter. This suggests that the company's growth rate is slowing down, which could be a cause for concern.







Idexx Laboratories Inc's Segments
CAG revenue    91.48 % of total Revenue
Water revenue    5.14 % of total Revenue
LPD revenue    2.97 % of total Revenue
Other revenue    0.45 % of total Revenue
CAG Diagnostics recurring revenue CAG revenue    80.35 % of total Revenue
IDEXX VetLab consumables CAG revenue    33.76 % of total Revenue
Rapid assay products CAG revenue    9.51 % of total Revenue
Reference laboratory diagnostic and consulting services CAG revenue    33.68 % of total Revenue
CAG Diagnostics services and accessories CAG revenue    3.4 % of total Revenue
CAG Diagnostics capital - instruments CAG revenue    3.03 % of total Revenue
Veterinary software services and diagnostic imaging systems CAG revenue    8.1 % of total Revenue
Recurring revenue CAG revenue    6.63 % of total Revenue
Systems and hardware CAG revenue    1.47 % of total Revenue
United States    65.44 % of total Revenue
Europe the Middle East and Africa    20.37 % of total Revenue
Asia Pacific Region    8.3 % of total Revenue
Canada    3.79 % of total Revenue
Latin America Caribbean    2.15 % of total Revenue
CAG    91.48 % of total Revenue
Water    5.14 % of total Revenue
LPD    2.97 % of total Revenue
Other    0.45 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com